BioNJ expanded its work with ARPA-H opportunities.
Public source
Publisher name
Public post
Beyond the Psychedelic Experience: Can We Make the Benefit Last? From Smart Pills to the potential of PT150 in psychedelic-enabled medicine, our work with ARPA-H opportu…
Company
BioNJ
Because Patients Can't Wait®
- Industry
- Biotechnology Research
- Location
- Trenton, US
- Company size
- 11–50 employees
About BioNJ
As the largest life sciences association in New Jersey, BioNJ is a powerful network of over 400 Member companies representing research-based life sciences companies and stakeholders. Because Patients Can’t Wait®, we are dedicated to propelling the rich innovation ecosystem in the New Jersey region to stimulate and support innovation, improve and save lives, and lower the hurdles of healthcare advancements for society. As the industry’s voice in New Jersey, we fulfill our mission by ensuring that: Science is Supported Companies are Created Drugs are Developed Patients are Paramount
See moreLatest activity
Latest activity from BioNJ
9 signals
Presence & Recognition
BioNJ announced a new partnership with the Convergence of Life Sciences Healthcare activity.
Presence & Recognition
BioNJ announced that its Manufacturing Summit sold out with a waitlist starting.
Presence & Recognition
BioNJ is hosting an Entrepreneurs Exchange event on September 23 featuring C-level entrepreneurs Dr. Izi Stoll of Numeria and Gerard Eldering of Perfusion Medical.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Biotechnology Innovation Organization
Biotechnology Innovation Organization commented on the FDA Expedited IND Pilot Program, backing its rolling review concept.
Research & Knowledge
Advanced Research Projects Agency for Health (ARPA-H)
Advanced Research Projects Agency for Health (ARPA-H) announced research funding for teams selected to build a new model for individualized RNA medicines.
Research & Knowledge
MassBio
MassBio reports that in 2025, Massachusetts companies out-licensed $10.9 billion across 27 deals.
Research & Knowledge
MatTek Life Sciences
MatTek Life Sciences published an article in Microtissue Matters by Alex Armento discussing NAMs adoption and its impact on R&D.
Research & Knowledge
Sano Genetics